Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.88 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.71 |
| ▸ | CTSD | P07339 | 4/20 | 0.71 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167805 | 0.93 | BACE1 (0.77) | BACE1BACE2CTSDAPP | |
| SCHEMBL13229734 | 0.93 | BACE1 (0.76) | BACE1BACE2CTSDAPP | |
| SCHEMBL8248360 | 0.90 | BACE1 (0.72) | BACE1BACE2CTSDAPP | |
| SCHEMBL13316941 | 0.88 | BACE1 (0.74) | BACE1BACE2CTSDAPP | |
| SCHEMBL13316840 | 0.85 | BACE1 (0.83) | BACE1BACE2CTSDAPP | |
| SCHEMBL13316940 | 0.85 | BACE1 (0.67) | BACE1BACE2CTSDAPP | |
| SCHEMBL8119831 | 0.84 | BACE1 (0.65) | BACE1BACE2CTSDAPP | |
| SCHEMBL27706055 | 0.84 | BACE1 (0.77) | BACE1BACE2CTSDAPP | |
| SCHEMBL3446848 | 0.84 | BACE1 (0.77) | BACE1BACE2CTSDAPP | |
| SCHEMBL16167843 | 0.84 | BACE1 (0.85) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATION GMNB (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144681-A1 | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN1, PSEN2, ADORA3 | BACE1 5/4885BACE2 23/4885CTSD 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.